Skip to main content

Table 3 Rates of clinical tumor regression in studies of adoptive transfer of tumor-reactive lymphocytes

From: Progress and controversies in developing cancer vaccines

Type of therapy Initial rate of objective responses Subsequent rate of objective responses Conclusion
LAK cell therapy + high-dose (HD) IL2 44% (11/25) [ref 34] 22% (23/106) [ref 35] Response rate not better than HD IL2 alone (28 vs 22%), but trend toward improved survival with LAK+IL2 for melanoma (p = 0.064) [refs 36,37]
TIL therapy + HD IL2 55% (11/20) [ref 38] 22% (9/41) [ref 39] Not better than HD IL2 alone [ref 39]. Median duration of partial responses 4 months [ref 40].
Selected TIL therapy after lymphoablation + HD IL2 51% (18/35) [ref 33] Pending Results preliminary